Doctors diagnose nearly 1,200 Texans under 20 years of age with cancer every year. Despite intensive genotoxic therapy, nearly 20% of these children will die from their cancer. Those who survive face a lifetime of potential toxicities due to their therapy.
CPRIT awarded a $4 million grant to The University of Texas Health Science Center at San Antonio to establish the Texas Pediatric Cancer Drug Testing Core (TPC-DTC) facility with resources available for academics and pharmaceutical firms in Texas. Researchers use this core to evaluate new drugs using patient-derived cancer models and to guide pediatric clinical development of novel agents and combinations.
Led by Raushan Kurmasheva, Ph.D., the TPC-DTC provides study design services, drug testing, genomics guidance, tissue microarrays that encompass pediatric cancers, and much more. The TPC-DTC has created over 200 patient-derived cancer models representing solid tumors, brain tumors, and leukemias. The childhood cancer models created by the TPC-DTC allows researchers and pharmaceutical companies to test novel treatments on these models matched with known genetic characteristics.
http://2024annualreport.cprit.texas.gov/our-mission-map-spotlights/#article2226
Since 2004, UT Health San Antonio, Greehey Children’s Cancer Research Institute’s (Greehey CCRI) mission has been to advance scientific knowledge relevant to childhood cancer, contribute to understanding its causes, and accelerate the translation of knowledge into novel therapies. Greehey CCRI strives to have a national and global impact on childhood cancer by discovering, developing, and disseminating new scientific knowledge. Our mission consists of three key areas — research, clinical, and education.
Stay connected with the Greehey CCRI on Facebook, Twitter, LinkedIn, and Instagram.